Stokes Family Office LLC Increases Stock Holdings in Inogen, Inc. (NASDAQ:INGN)

Stokes Family Office LLC lifted its position in Inogen, Inc. (NASDAQ:INGN) by 29.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 163,500 shares of the medical technology company’s stock after purchasing an additional 36,715 shares during the period. Stokes Family Office LLC’s holdings in Inogen were worth $1,499,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC purchased a new stake in shares of Inogen in the fourth quarter worth about $43,000. Quarry LP purchased a new stake in shares of Inogen in the third quarter worth about $59,000. Ieq Capital LLC purchased a new stake in shares of Inogen in the fourth quarter worth about $94,000. Intech Investment Management LLC purchased a new stake in Inogen in the fourth quarter valued at approximately $94,000. Finally, Verition Fund Management LLC purchased a new stake in Inogen in the third quarter valued at approximately $106,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Price Performance

Shares of INGN opened at $7.33 on Wednesday. Inogen, Inc. has a 1-year low of $6.14 and a 1-year high of $13.33. The firm’s 50 day simple moving average is $9.88 and its 200 day simple moving average is $9.76. The company has a market capitalization of $194.46 million, a P/E ratio of -3.26 and a beta of 1.15.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on INGN. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Wednesday, February 26th. StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.